Heparin vs. aspirin
This article was originally published in The Tan Sheet
Low-molecular-weight heparin is not superior to aspirin in treating acute ischemic stroke in patients with atrial fibrillation, Berge, et al., Ulleval University Hospital, Oslo, Norway conclude in a study published in the April 8 Lancet. In a randomized, double-blind, double-dummy trial of 449 patients with acute ischemic stroke and atrial fibrillation, the researchers examined whether 100 IU/kg subcutaneous LMWH treatment twice daily, started within 30 hours of stroke onset, is superior to 160 mg aspirin per day at preventing recurrent stroke during the first two weeks. Berge, et al. say they "cannot exclude the possibility of smaller, but still worthwhile, effects of either of the trial drugs," and suggest patients receive aspirin in the acute phase of stroke and that short-term prophylactic use of low-dose LMWH should be considered
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: